This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to optimize equitable peanut allergy prevention among high-risk infants. The award of $194,911 supports a study led by Dr. Julie Flom at Yale University that will explore multi-level sociodemographic determinants of peanut introduction in high-risk infants, examine facilitators and barriers to guideline-concordant care, and pilot a...
This $300,000 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant was awarded to Cellergy Pharma Inc. to develop an innovative bispecific antibody drug that can efficiently and specifically eliminate IgE-producing B cells to treat severe allergic diseases. The key objectives of this Phase I project are to determine the potency of the drug in eliminating IgE-producing...
This Cooperative Agreement awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships program (CFDA 47.084) provides $1,000,000 in funding to Alerje, Inc., a minority-owned small disadvantaged business located in Detroit, Michigan. The award supports the development of a comprehensive digital platform to improve care and support the implementation of emerging food allergy oral immunotherapy treatments. The platform includes an innovative epinephrine...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on understanding the mechanisms of increased intestinal epithelial cell (IEC) barrier permeability in peanut allergy. The $202,314 grant supports a 5-year research and career development program for Dr. Erin Steinbach, a tenure-track Assistant Professor at the University of North Carolina (UNC) School of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $264,596 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Trustees of the University of Pennsylvania. The grant, awarded on August 9, 2024, supports a prospective randomized study to assess whether serum microRNA (miRNA) profiling can assist in the safe tapering of immunosuppression in liver transplant recipients, when compared to clinically guided management. The study aims...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to determine the role of immunomodulatory metabolites in the remission of food allergies induced by immunotherapy. The $1,018,525 award will fund research to validate the presence of protective metabolomic signatures, such as bile acids, arachidonic acids, and histidine pathways, in children who develop remission from food...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded Qrono, Inc. a $306,500 Project Grant on July 22, 2024. The grant supports the development of QR402, a first-in-class oral nanomedicine therapy that targets intestinal dendritic cells to restore immunological tolerance and prevent the onset of type 1 diabetes. The project aims to characterize the tolerogenic properties of the AMPK pathway agonist...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research into a bifunctional IgE antagonist and dissociator (ANDI) drug candidate. The goal is to develop an innovative treatment that can both antagonize and dissociate IgE receptor-bound on mast cells, thereby reducing airway hyperreactivity and improving lung function in patients with severe allergic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $293,680 to Antiger Therapeutics Inc. to develop targeted immunotherapies for celiac disease (CD). The primary objective is to generate a biologic that blocks the pathogenic T cells recognizing the gluten peptide-DQ2 complex, a key factor in the autoimmune response underlying CD. Specifically, the award will fund the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,245,701 to the University of Pittsburgh to research mechanisms of allergen-induced tolerance in the lung. The goal is to develop a better understanding of how repeated exposure to low doses of allergens, such as house dust mite, can prevent adverse reactions upon subsequent exposure. Key focus areas include...